Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03867045 · ClinicalTrials.gov registry record · NA
Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer
A NA study, sponsored by Duke University.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03867045 is a NA study that was terminated before completion, run by Duke University. The registered enrollment target is 1 participants.
The verdict
NCT03867045, a NA study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.
Interventions
- DEVICE Usability of an electronic symptom management application
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-08-21 |
| Est. Completion | 2019-12-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03867045
The ClinicalTrials.gov registry entry for NCT03867045 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Usability of an electronic symptom management application is the first listed.
NCT03867045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03867045 about?
NCT03867045 is a clinical study titled "Development of a Cabozantinib (Cabometyx) Symptom Management Application for Use in Patients With Renal Cancer". The purpose of this study is to develop an on-line electronic symptom management application that can ultimately be used to improve clinical outcomes in patients with mRCC treated with cabozantinib.
What is the current status of trial NCT03867045?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2019-08-21. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT03867045?
The interventions under investigation include: Usability of an electronic symptom management application (DEVICE).
Who is sponsoring clinical trial NCT03867045?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.